[go: up one dir, main page]

RU2015117267A - Замещенные соединения амида - Google Patents

Замещенные соединения амида Download PDF

Info

Publication number
RU2015117267A
RU2015117267A RU2015117267/04A RU2015117267A RU2015117267A RU 2015117267 A RU2015117267 A RU 2015117267A RU 2015117267/04 A RU2015117267/04 A RU 2015117267/04A RU 2015117267 A RU2015117267 A RU 2015117267A RU 2015117267 A RU2015117267 A RU 2015117267A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
benign prostatic
prostatic hyperplasia
acceptable salt
bladder
Prior art date
Application number
RU2015117267/04A
Other languages
English (en)
Other versions
RU2609021C2 (ru
Inventor
Эйдзи КАВАМИНАМИ
Тацухиса ТАКАХАСИ
Такатоси КАНАЯМА
Юта ФУКУДА
Хироюки Каизава
Ютака КОНДОХ
Рюси Сео
Казуюки КУРАМОТО
Казухико ТАКЕ
Казуюки САКАМОТО
Original Assignee
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк.
Publication of RU2015117267A publication Critical patent/RU2015117267A/ru
Application granted granted Critical
Publication of RU2609021C2 publication Critical patent/RU2609021C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

1. 2-({[(2-Циано-4-метоксифенил)ацетил](3-фенилпропил)-амино}метил)-N-(диметилсульфамоил)-5-метил-1,3-тиазол-4-карбоксамид или его фармацевтически приемлемая соль.2. Соединение по п. 1 или его фармацевтически приемлемая соль для предотвращения и/или лечения заболеваний, вызванных ЛФК, выбранных из группы, состоящей из доброкачественной гиперплазии предстательной железы, дисфункции мочевыводящих путей, связанной с доброкачественной гиперплазией предстательной железы, склероза шейки пузыря, гипоактивного мочевого пузыря.3. Фармацевтическая композиция, обладающая антагонистической активностью в отношении ЛФК рецептора, содержащая эффективное количество соединения или его фармацевтически приемлемой соли по п. 1 и фармацевтически приемлемый наполнитель.4. Фармацевтическая композиция для предотвращения и/или лечения заболеваний, вызванных ЛФК, выбранных из группы, состоящей из доброкачественной гиперплазии предстательной железы, дисфункции мочевыводящих путей, связанной с доброкачественной гиперплазией предстательной железы, склероза шейки пузыря, гипоактивного мочевого пузыря, содержащая эффективное количество соединения или его фармацевтически приемлемой соли по п. 1 и фармацевтически приемлемый наполнитель.5. Применение соединения или его фармацевтически приемлемой соли по п. 1 для получения фармацевтической композиции для предотвращения и/или лечения заболеваний, вызванных ЛФК, выбранных из группы, состоящей из доброкачественной гиперплазии предстательной железы, дисфункции мочевыводящих путей, связанной с доброкачественной гиперплазией предстательной железы, склероза шейки пузыря, гипоактивного моч�

Claims (7)

1. 2-({[(2-Циано-4-метоксифенил)ацетил](3-фенилпропил)-амино}метил)-N-(диметилсульфамоил)-5-метил-1,3-тиазол-4-карбоксамид или его фармацевтически приемлемая соль.
2. Соединение по п. 1 или его фармацевтически приемлемая соль для предотвращения и/или лечения заболеваний, вызванных ЛФК, выбранных из группы, состоящей из доброкачественной гиперплазии предстательной железы, дисфункции мочевыводящих путей, связанной с доброкачественной гиперплазией предстательной железы, склероза шейки пузыря, гипоактивного мочевого пузыря.
3. Фармацевтическая композиция, обладающая антагонистической активностью в отношении ЛФК рецептора, содержащая эффективное количество соединения или его фармацевтически приемлемой соли по п. 1 и фармацевтически приемлемый наполнитель.
4. Фармацевтическая композиция для предотвращения и/или лечения заболеваний, вызванных ЛФК, выбранных из группы, состоящей из доброкачественной гиперплазии предстательной железы, дисфункции мочевыводящих путей, связанной с доброкачественной гиперплазией предстательной железы, склероза шейки пузыря, гипоактивного мочевого пузыря, содержащая эффективное количество соединения или его фармацевтически приемлемой соли по п. 1 и фармацевтически приемлемый наполнитель.
5. Применение соединения или его фармацевтически приемлемой соли по п. 1 для получения фармацевтической композиции для предотвращения и/или лечения заболеваний, вызванных ЛФК, выбранных из группы, состоящей из доброкачественной гиперплазии предстательной железы, дисфункции мочевыводящих путей, связанной с доброкачественной гиперплазией предстательной железы, склероза шейки пузыря, гипоактивного мочевого пузыря.
6. Применение соединения или его фармацевтически приемлемой соли по п. 1 для предотвращения и/или лечения заболеваний, вызванных ЛФК, выбранных из группы, состоящей из доброкачественной гиперплазии предстательной железы, дисфункции мочевыводящих путей, связанной с доброкачественной гиперплазией предстательной железы, склероза шейки пузыря, гипоактивного мочевого пузыря.
7. Способ предотвращения и/или лечения заболеваний, вызванных ЛФК, выбранных из группы, состоящей из доброкачественной гиперплазии предстательной железы, дисфункции мочевыводящих путей, связанной с доброкачественной гиперплазией предстательной железы, склероза шейки пузыря, гипоактивного мочевого пузыря, включающий введение пациенту эффективного количества соединения или его фармацевтически приемлемой соли по п. 1.
RU2015117267A 2009-09-25 2010-09-24 Замещенные соединения амида RU2609021C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009-220316 2009-09-25
JP2009220316 2009-09-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2012116505/04A Division RU2563639C2 (ru) 2009-09-25 2010-09-24 Замещенные соединения амида

Publications (2)

Publication Number Publication Date
RU2015117267A true RU2015117267A (ru) 2015-11-10
RU2609021C2 RU2609021C2 (ru) 2017-01-30

Family

ID=43795936

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2012116505/04A RU2563639C2 (ru) 2009-09-25 2010-09-24 Замещенные соединения амида
RU2015117267A RU2609021C2 (ru) 2009-09-25 2010-09-24 Замещенные соединения амида

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2012116505/04A RU2563639C2 (ru) 2009-09-25 2010-09-24 Замещенные соединения амида

Country Status (17)

Country Link
US (2) US8669246B2 (ru)
EP (1) EP2481725B1 (ru)
JP (1) JP5708936B2 (ru)
KR (1) KR101678255B1 (ru)
CN (1) CN102548965B (ru)
AU (1) AU2010299114A1 (ru)
BR (2) BR112012006686B8 (ru)
CA (1) CA2774647C (ru)
ES (1) ES2532866T3 (ru)
IL (1) IL218723A0 (ru)
MX (1) MX2012003560A (ru)
PL (1) PL2481725T3 (ru)
PT (2) PT2481725E (ru)
RU (2) RU2563639C2 (ru)
TW (1) TW201117809A (ru)
WO (1) WO2011037192A1 (ru)
ZA (1) ZA201202106B (ru)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2563639C2 (ru) 2009-09-25 2015-09-20 Астеллас Фарма Инк. Замещенные соединения амида
PH12012500542A1 (en) * 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound
HU1000676D0 (en) * 2010-12-17 2011-02-28 Pharmahungary 2000 Kft Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
WO2013064983A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
JP6058023B2 (ja) * 2011-12-15 2017-01-11 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ スルホンアミド誘導体
AU2013266398A1 (en) 2012-05-22 2015-01-22 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
CN103102325B (zh) * 2013-01-16 2014-11-12 浙江大学宁波理工学院 一种2-溴代甲基-4-羧酸乙酯噻唑的合成方法
CA2898679A1 (en) 2013-03-14 2014-09-25 Xenon Pharmaceuticals Inc. Substituted triazolopyridines and methods of use thereof
RU2015143834A (ru) 2013-03-15 2017-04-24 Дженентек, Инк. Замещенные бензоксазолы и способы их применения
US10201614B2 (en) 2013-03-15 2019-02-12 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
CN103467281B (zh) * 2013-07-25 2016-03-23 武汉英纳氏药业有限公司 一种苯酚衍生物及其应用
GB201314926D0 (en) 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
BR112016015105A8 (pt) 2013-12-27 2018-04-24 Var2 Pharmaceuticals Aps conjugados var2csa-droga
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10450378B2 (en) 2014-09-17 2019-10-22 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2016053107A1 (en) * 2014-10-03 2016-04-07 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
CN106243003B (zh) * 2015-06-03 2018-03-09 上海海雁医药科技有限公司 环烃基取代的甲磺酰基苯甲酰胺衍生物、其制法与医药上的用途
US11525024B2 (en) 2015-07-13 2022-12-13 University Of Delaware Bio-based polymers from raw lignocellulosic biomass
US10253131B2 (en) * 2015-07-13 2019-04-09 University Of Delaware Polymers prepared from functionalized dimethoxyphenol monomers
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
CN105085235A (zh) * 2015-08-31 2015-11-25 彭静 拆分制备s-4-氯扁桃酸的方法
CN105085245A (zh) * 2015-08-31 2015-11-25 彭静 一种r-4-氟扁桃酸的制备方法
CN105085244A (zh) * 2015-08-31 2015-11-25 彭静 一种r-4-溴苦杏仁酸的制备方法
CN105152913A (zh) * 2015-08-31 2015-12-16 彭静 S-4-氟扁桃酸的制备方法
CN105085234A (zh) * 2015-08-31 2015-11-25 彭静 一种r-4-氯扁桃酸的制备方法
CN105061190A (zh) * 2015-09-02 2015-11-18 彭静 拆分制备s-五氟苦杏仁酸的方法
CN105085236A (zh) * 2015-09-02 2015-11-25 彭静 R-五氟苦杏仁酸的拆分制备方法
CN105085248A (zh) * 2015-09-02 2015-11-25 彭静 拆分制备s-4-甲氧基扁桃酸的方法
CN105085246A (zh) * 2015-09-02 2015-11-25 彭静 一种r-邻氯扁桃酸的制备方法
CN105085247A (zh) * 2015-09-02 2015-11-25 彭静 拆分制备r-4-甲氧基扁桃酸的方法
JP6987746B2 (ja) 2015-09-28 2022-01-05 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
WO2017137456A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
US10874746B2 (en) 2016-02-08 2020-12-29 Synaffix B.V. Sulfamide linkers for use in bioconjugates
US11590239B2 (en) 2016-02-08 2023-02-28 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
MA46546A (fr) 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
HRP20230243T1 (hr) * 2018-06-07 2023-04-14 Idorsia Pharmaceuticals Ltd Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze
AR119162A1 (es) * 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
US20220251342A1 (en) 2019-08-09 2022-08-11 Konica Minolta, Inc. Resin composition, filamentous material, three-dimensional additively manufactured object, and method for producing three-dimensional additively manufactured object
KR102775995B1 (ko) 2019-11-15 2025-03-11 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CA3185689A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022241023A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN118541360A (zh) 2021-12-08 2024-08-23 吉利德科学公司 Lpa受体拮抗剂及其用途
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019513A2 (en) 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Methods for detecting compounds which modulate the activity of an lpa receptor
ES2320320T3 (es) 2000-02-18 2009-05-21 Kyowa Hakko Kirin Co., Ltd. Nuevos compuestos de isoxazol y tiazol y uso de los mismos como farmacos.
ATE447970T1 (de) 2001-02-08 2009-11-15 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
US7285680B2 (en) 2002-05-28 2007-10-23 Ono Pharmaceutical Co., Ltd. β-alanine derivatives and the use thereof
EP1550461A1 (en) 2002-06-26 2005-07-06 Ono Pharmaceutical Co., Ltd. Remedy for chronic disease
JP2005538162A (ja) * 2002-09-06 2005-12-15 イーラン ファーマスーティカルズ、インコーポレイテッド １，３−ジアミノ−２−ヒドロキシプロパンプロドラッグ誘導体
AU2003241836A1 (en) 2002-10-03 2004-04-23 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
TW200521108A (en) 2003-12-19 2005-07-01 Ono Pharmaceutical Co Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
JP5225098B2 (ja) * 2005-12-14 2013-07-03 ブリストル−マイヤーズ スクイブ カンパニー 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
TW200736234A (en) * 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
CA2754551C (en) * 2008-03-03 2016-09-13 Rxbio, Inc. Lpa receptor agonists and antagonists
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
RU2563639C2 (ru) 2009-09-25 2015-09-20 Астеллас Фарма Инк. Замещенные соединения амида
PH12012500542A1 (en) 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound

Also Published As

Publication number Publication date
JPWO2011037192A1 (ja) 2013-02-21
JP5708936B2 (ja) 2015-04-30
BR112012006686B1 (pt) 2021-02-09
ES2532866T3 (es) 2015-04-01
US8815920B2 (en) 2014-08-26
CN102548965B (zh) 2014-04-09
RU2563639C2 (ru) 2015-09-20
IL218723A0 (en) 2012-06-28
KR101678255B1 (ko) 2016-11-21
ZA201202106B (en) 2013-05-29
CN102548965A (zh) 2012-07-04
PL2481725T3 (pl) 2015-08-31
US8669246B2 (en) 2014-03-11
KR20120078700A (ko) 2012-07-10
US20120184521A1 (en) 2012-07-19
CA2774647C (en) 2017-03-28
TW201117809A (en) 2011-06-01
AU2010299114A1 (en) 2012-04-12
MX2012003560A (es) 2012-10-05
RU2609021C2 (ru) 2017-01-30
PT2481725E (pt) 2015-05-21
EP2481725B1 (en) 2015-03-04
RU2012116505A (ru) 2013-11-20
WO2011037192A1 (ja) 2011-03-31
EP2481725A1 (en) 2012-08-01
EP2481725A4 (en) 2013-03-20
BR112012006686A2 (pt) 2016-05-10
CA2774647A1 (en) 2011-03-31
US20130231320A1 (en) 2013-09-05
PT2620433E (pt) 2015-06-22
BR112012006686B8 (pt) 2021-05-25
BR112013006936A2 (pt) 2016-07-19

Similar Documents

Publication Publication Date Title
RU2015117267A (ru) Замещенные соединения амида
RU2470016C2 (ru) Производное бипиразола
HRP20120866T1 (hr) Makrocikliäśni spojevi hinoksalina kao inhibitori hcv ns3 proteaze
RU2012124268A (ru) Бензимидазольные соединения и их применения
MX344308B (es) Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
HRP20160355T1 (hr) Kristalni oblici 4-[5-[3-kloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-izoksazolil]-n-[2-okso-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenkarboksamida
TW200607807A (en) Macrocyclic beta-secretase inhibitors
RU2014122858A (ru) Лечение когнитивных расстройств (r)-7-хлор-n-(хинуклидин-3-ил)бензо[в]тиофен-2-карбосамидом и его фармацевтически приемлемыми солями
CY1113670T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης
ZA200802811B (en) Therapy for the treatment of disease
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
CN107105660A (zh) 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
RU2011117927A (ru) Карбаматное соединение или его соль
JP2011527333A5 (ru)
RU2012145116A (ru) Фармацевтическая композиция для предупреждения или лечения неалкогольного жирового гепатоза и способ предупреждения или лечения неалкогольного жирового гепатоза с ее использованием
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
RU2009133262A (ru) Нападизилатная соль антагониста мускаринового мз-рецептора
MX2012001160A (es) Agonistas del receptor de esfingosina-1-fosfato.
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
RU2007132725A (ru) Применение неопиатного анальгетика флупиртина для лечения гиперактивности мочевого пузыря и родственных заболеваний, в том числе неотложного недержания мочи, проблем с мочеотделением, как результата гиперплазии предстательной железы и синдрома раздраженного кишечника
EA019037B1 (ru) 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application